Endo Pharmaceuticals (ENDP) Receives Complete Response From FDA On FORTESTA
More News related to ENDP
- Shares of Endo Pharma (ENDP) Tumbling as Citi Downgrades Intraday
- Endo Pharma (ENDP) Partners Receive Paragraph IV Cert for LIDODERM ANDA Filing
- Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
- Endo to Present at J.P. Morgan 28th Annual Healthcare Conference
- Notable Analyst Ratings Changes 12/08: UAUA, CBS, STP, JASO, AGU, SYY Upgraded; S, ENDP, CCJ, BEAV Downgraded
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Endo Pharmaceuticals (Nasdaq: ENDP) received a Complete Response letter from the FDA regarding the New Drug Application for FORTESTA 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.
"The potential of this action was considered in the structure of the deal to in-license this product," said Dr. Ivan Gergel, M.D., executive vice president, R&D, Endo Pharmaceuticals. "We will continue to work closely with the FDA to address their questions and we expect to file a complete response, mid-2010. Endo is committed to bringing FORTESTA to market to offer men another option for testosterone replacement therapy."
Related Categories
FDAStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
